X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ACM-001.1 (S-pindolol benzoate) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2/3 clinical data in cachexia associated with colorectal cancer (IMPACT CRC) and another in patients with non-small cell lung cancer.
Lead Product(s): S-pindolol Benzoate
Therapeutic Area: Oncology Product Name: ACM-001.1
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
The investment will support the development of the Actimed pipeline, including ACM-001.1 (S-pindolol benzoate), with preparations under way for a Phase 2b/3 programme targeted at the treatment of cancer cachexia in non-small cell lung cancer and colorectal cancer.
Lead Product(s): S-pindolol Benzoate
Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-001.1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mankind Pharma
Deal Size: $6.3 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 26, 2023
Details:
ACM-001.1 (S-pindolol benzoate) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2a clinical data in cachexia patients.
Lead Product(s): Pindolol
Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-001.1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mankind Pharma
Deal Size: $12.1 million Upfront Cash: Undisclosed
Deal Type: Financing January 04, 2023
Details:
S-oxprenolol is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed and this newest patent completes the global patent estate relating to the treatment of ALS with S-oxprenolol.
Lead Product(s): Pindolol
Therapeutic Area: Musculoskeletal Product Name: ACM-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021
Details:
The proceeds will allow Actimed to further advance the development of its lead compound, S-pindolol (ACM-001.1), for cancer cachexia, by performing a Pharmacokinetic (PK) and Pharmacodynamic (PD) study due to start later this year.
Lead Product(s): Pindolol
Therapeutic Area: Oncology Product Name: ACM-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $3.4 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 10, 2021
Details:
Faraday gains global rights to develop and commercialize S-oxprenolol for cancer cachexia and any other indications outside of amyotrophic lateral sclerosis (ALS).
Lead Product(s): Oxprenolol
Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-002
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Faraday Pharmaceuticals
Deal Size: $134.7 million Upfront Cash: $2.7 million
Deal Type: Licensing Agreement April 13, 2021
Details:
ACM-002 (S-oxprenolol) is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed. The new patent contains claims which cover the treatment of the symptoms of cachexia in patients having a late stage cancer.
Lead Product(s): Oxprenolol
Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-002
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
Actimed Therapeutics has licensed additional European patent rights to S-oxprenolol in amyotrophic lateral sclerosis (ALS) from Charité – Universitätsmedizin Berlin (Charité). This gives Actimed global rights in this indication.
Lead Product(s): Oxprenolol
Therapeutic Area: Neurology Product Name: ACM-002
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Charité Universitätsmedizin
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
